Higher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy

References

• Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61–71.
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, et al. Human prostate cancer risk factors. Cancer 2004;101:2371–490.
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer. I: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293–7.
   Google Scholar
• Huggins C, Stevens RE. The effect of castration on benign hypertrophy of the prostate in man. J Urol 1940;43:705–14.
   Google Scholar
• Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55:310–20.
   PubMed Web of Science ®Google Scholar
• Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J Clin Endocrinol Metab 1991;73:1016–25.
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833–76.
   PubMed Web of Science ®Google Scholar
• Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001;47:52–8.
   PubMed Web of Science ®Google Scholar
• Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118–26.
   PubMed Web of Science ®Google Scholar
• Stattin P, Lumme S, Tenkanen L, Alfthan H, Jellum E, Hallmans G, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004;108:418–24.
   PubMed Web of Science ®Google Scholar
• Morgentaler A. Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur Urol 2007;52:623–5.
   PubMed Web of Science ®Google Scholar
• Morgentaler A. Rapidly shifting concepts regarding androgens and prostate cancer. Sci World J 2009;9:685–90.
   Google Scholar
• Morote J, Trilla E, Esquena S, Serrallach F, Abascal JM, Muñoz A, et al. The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 4.1 and 10 ng/ml. Eur Urol 2002;42:333–7.
   Google Scholar
• Karamanolakis D, Lambou T, Bogdanos J, Milathianakis C, Sourla A, Lembessis P, et al. Serum testosterone: a potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (greater than or 3.0 and less than 10.0 ng/ml). Anticancer Res 2006;26:3159–66.
   PubMed Web of Science ®Google Scholar
• Rhoden EL, Riedner CE, Morgentaler A. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. J Urol 2008;179:1741–4.
   PubMedGoogle Scholar
• García-Cruz E, Huguet J, Piqueras M, Márquez MP, Peri L, Izquierdo L, et al. Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy. World J Urol 2012;30:361–5.
   Google Scholar
• García-Cruz E, Piqueras M, Huguet J, Peri L, Izquierdo L, Musquera M, et al. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. BJU Int 2012; May 15; doi: 10.1111/j.1464-410X. 2012.11232.x. [Epub ahead of print].
   Google Scholar
• García-Cruz E, Piqueras M, Ribal MJ, Huguet J, Serapiao R, Peri L. Low testosterone level predicts prostate cancer in re-biopsy in patients with high grade prostatic intraepithelial neoplasia. BJU Int 2012;110:E199–202.
   Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–72.
   PubMed Web of Science ®Google Scholar
• Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events Trial. Eur Urol 2012;62:757–64.
   PubMed Web of Science ®Google Scholar
• Morgentaler A. Goodbye androgen hypothesis, hello saturation model. Eur Urol 2012;62:765–7.
   Google Scholar
• Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005;41:834–45.
   PubMed Web of Science ®Google Scholar
• Vatten LJ, Ursin G, Ross RK, Stanczyk FZ, Lobo RA, Harvei S, et al. Androgens in serum and the risk of prostate cancer: a nested case–control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev 1997;6:967–9.
   PubMed Web of Science ®Google Scholar
• Mohr BA, Feldman HA, Kalish LA, Longcope C, McKinlay JB. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 2001;57:930–5.
   PubMedGoogle Scholar
• Platz EA, Leitzmann MF, Rifai N, Kantoff KW, Chen YC, Stampfer MJ, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005;14:1262–9.
   PubMed Web of Science ®Google Scholar
• Severi G, Morris HA, Maclnnis RJ, English DR, Tilley W, Hopper JL, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:86–91.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/ml or less. Urology 2006;68:1263–7.
   PubMed Web of Science ®Google Scholar
• Sofikerim M, Eskicorapci S, Oruç O, Ozen H. Hormonal predictors of prostate cancer. Urol Int 2007;79:13–18.
   Google Scholar
• Yano M, Imamoto T, Suzuki H, Fukasawa S, Kojima S, Komiya A, et al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol 2007;51:375–80.
   PubMed Web of Science ®Google Scholar
• Mearini L, Costantini E, Zucchi A, Mearini E, Bini V, Cottini E, et al. Testosterone levels in benign prostatic hypertrophy and prostate cancer. Urol Int 2008;80:134–40.
   PubMed Web of Science ®Google Scholar
• Morote J, Ramirez C, Gómez E, Planas J, Raventós CX, de Torres IM, et al. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU Int 2009;104:486–9.
   PubMed Web of Science ®Google Scholar
• Morote J, Planas J, Ramirez C, Gomez E, Raventós CX, Placer J, et al. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. BJU Int 2010;105:481–4.
   Google Scholar
• Koo JM, Shim SM. Significance of serum testosterone for prostate-specific antigen (PSA) elevation and prediction of prostate cancer in patients with PSA above 10 ng/ml. Korean J Urol 2010;51:831–5.
   Google Scholar
• Grosman H, Fabre B, Mesch V, Lopez MA, Schreier L, Mazza O, et al. Lipoproteins, sex hormones and inflammatory markers in association with prostate cancer. Aging Male 2010;13:87–92.
   PubMed Web of Science ®Google Scholar